Biomaker

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Jul 7, 2025

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time Broomfield, CO, July 7, 2025 - PRISM MediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has...

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Jun 25, 2025

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY...

Aclarion Welcomes Advocate Health as CLARITY Trial Site

May 5, 2025

Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Press Audio: BROOMFIELD, Colo., May 05, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 29, 2025

Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries Listen: Broomfield, CO, April 29, 2025 – PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help...

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 9, 2025

Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 Broomfield, CO, April 9, 2025 - PRISM MediaWire -Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with...

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 31, 2025

Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 Broomfield, CO, March 31, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary...

TransGlobal Assets (OTC: TMSH) Names Michael Berman as CEO

Mar 18, 2025

Key Highlights: TransGlobal Assets Inc. (OTC: TMSH) Appoints Michael Berman as CEOFollowing the acquisition of Mindwell Solutions Group LLC, TransGlobal Assets names tech visionary Michael Berman as CEO to drive AI-powered mental health, relationship wellness, and performance analytics innovation. Expansion into AI-Powered Emotional Intelligence & Biometric AnalysisWith proprietary AI-driven technologies, TransGlobal aims to revolutionize human well-being through scalable solutions in...

Aclarion Provides Shareholder Update

Mar 13, 2025

Broomfield, CO, March 13, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review. The filing can be viewed here: The Company intends on filing its 10K by the end of March and...

NEWSROOM

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion Welcomes Advocate Health as CLARITY Trial Site

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

TransGlobal Assets (OTC: TMSH) Names Michael Berman as CEO

Aclarion Provides Shareholder Update

Contact Us